Orphan drug approvals of 2015: Europe and the United States

2016 ◽  
Vol 4 (5) ◽  
pp. 491-500 ◽  
Author(s):  
Peter Norman
Author(s):  
Bryan S. Walsh ◽  
Ameet Sarpatwari ◽  
Benjamin N. Rome ◽  
Aaron S. Kesselheim

2018 ◽  
Vol 29 ◽  
pp. viii563-viii564
Author(s):  
O.F. Khan ◽  
N.N. Samuel ◽  
S. Verma

2020 ◽  
Vol 27 (1) ◽  
pp. 23-31 ◽  
Author(s):  
Kathleen F. Edwards ◽  
Joel F. Liebman

Orphan drug products (e.g. drugs and biologics) in the United States are those that treat people with rare chronic diseases, often cancer or metabolic disease. The rare disease condition being treated by these orphan drugs must serve a patient population of less than 200,000 people in the U.S. in order to earn the orphan drug product title. Just as the disease conditions are seen as “orphans,” so, we assert is the thermochemical understanding of the drugs themselves in terms of the chemical structures that define those drugs. This article illustrates this orphan thermochemical status for a recent series of orphan drugs.


2020 ◽  
Author(s):  
Natalie Corina Munguia ◽  
B. Robert Mozayeni ◽  
Thomas Wright ◽  
Karen L. Herbst

Abstract Background In the United States (US), the Orphan Drug Act of 1983 defines a rare disease as affecting less than 200,000 individuals. In Europe, a rare disease or disorder is defined as affecting 5 individuals in 10,000 which the European commission reports to be approximately 246,000 individuals. Dercum’s disease, also known as Adiposis Dolorosa, is a rare loose connective (fat) tissue disease that is characterized by painful lipomas (fatty masses). Orphanet, the National Organization for Rare Disease (NORD) and the United States National Institutes of Health (NIH) have classified Dercum’s disease as a rare disorder. The prevalence of Dercum’s disease is not well studied or understood. The objective of this paper is to estimate the prevalence of Dercum’s disease, whether it is in fact a rare disease, and increase awareness for this painful disease. Results An in-depth literature review was conducted in PubMed, the UK Biobank, the U.S. Agency for Health Research and Quality Healthcare Cost and Utilization, by incidence of disease in medical practice, in social media forums and by internet search in order to understand, estimate and determine the prevalence of Dercum’s disease. The prevalence of Dercum’s disease was found to range from 150 to 150,000 in the US population. Conclusion The data collected in this paper meet the requirements of the Orphan Drug Act which requires 200,000 individuals or less to be affected by a disorder for it to be classified as rare. These conclusions may apply to Europe as supporting data was utilized from both Sweden and the UK. Further research must be conducted to better understand subclassifications of this rare disorder.


2011 ◽  
Vol 14 (7) ◽  
pp. A337
Author(s):  
B. Sepulveda ◽  
J. Doyle

Sign in / Sign up

Export Citation Format

Share Document